Transcatheter aortic valve implantation: The European experience  by Lange, Rüdiger et al.
Lange et al Panel 1Transcatheter aortic valve implantation: The European experienceR€udiger Lange, MD, PhD,a Sabine Bleiziffer, MD,a Yacine Elhmidi, MD,a and Nicolo Piazza, MD, PhDa,bFrom th
Germ
tiona
Mont
Disclos
regar
Read at
York,
Receive
for pu
Address
Techn
Muni
0022-52
Copyrig
http://dxThe European transcatheter aortic valve implantation experience began in 2002, and ever since, numerous cen-
ters have started a program, resulting in a ‘‘transcatheter aortic valve implantation pandemic.’’ Considerable ex-
perience has been gained with various access routes for implantation and with valve-in-surgical bioprosthetic
valve procedures. Reimbursement differs among the European countries and is currently undergoing rapid
changes. Accordingly, the implantation rates in various European countries still differ considerably, with the
greatest in Switzerland and Germany: 77 implants per 1 million treatable inhabitants. The Edwards Source
and the Medtronic Advance trials, designed as postcommercialization studies, demonstrated a steady improve-
ment in results, which was also reflected in the single-center mid-term data up to 3 years. The preliminary results
from national European registries have been remarkably comparable in terms of survival and stroke. The
‘‘glimpse into the future’’ points toward implantation in intermediate-risk patients in contrast to high-risk or in-
operable patients. The results of the Medtronic Surgical Replacement and Transcatheter Aortic Valve Implan-
tation and Edwards Placement of Aortic Transcatheter Valves Trial 2 trials will show whether this change in
paradigm is justified. (J Thorac Cardiovasc Surg 2013;145:S17-21)The European transcatheter aortic valve implantation
(TAVI) experience began in 2002, when Alain Cribier, 1
of the pioneers of transcatheter valves, implanted the first
balloon expandables Cribier-Edwards prosthesis using
a trans-septal approach in a 57-year-old male patient with
severe aortic stenosis in whom conventional aortic valve re-
placement had been declined.1 In 2006, Grube and col-
leagues2 published their first-in-man single-center
experience with 25 patients who underwent retrograde im-
plantation of the self-expandable CoreValve ReValving bi-
oprosthesis. The Medtronic CoreValve (Medtronic,
Minneapolis, Minn) and the Edwards SAPIEN (Edwards
LifeSciences, Irvine, Calif) prostheses obtained CE mark
approval in April 2007 and August 2007, respectively. In
October 2011, the Jena Valve (JenaValve Technology
GmbH, Munich, Germany) and the Symetis Acurate TA
(Symetis, Ecublens, Switzerland) received CE mark ap-
proval for transapical aortic valve implantation (Figure 1).3EXPERIENCE WITH VARIOUS ACCESS ROUTES
In Europe, TAVI is currently performed using
a transfemoral, transaxillary, transapical, and transaortic
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The Journal of Thoracic and Cara successful access route.10After the first-in-man description
of the subclavian and transaortic access approach in 2008
and 2009, respectively, many single- andmulticenter reports
have emerged.11,12 The results and techniques for the
transaortic approach were presented at the Annual Society
of Thoracic Surgeons meeting in 201213,14 (Table 1).
TRANSCATHETER AORTIC VALVE IN SURGICAL
AORTIC VALVE IMPLANTATION
Danny Dvir, MD, of the Rabin Medical Center (Petah
Tikva, Israel) presented data from the Global Valve-in-Valve
Registry at the 2011 Transcatheter Cardiovascular Therapeu-
tics 23rd Annual Scientific Symposium.15 The Medtronic
CoreValve and Edwards Sapien prostheses were implanted
in 63% and 37% of the 195 patients, respectively. The inves-
tigators concluded that the technique is clinically effective in
most patients and that the 1-year resultswere comparablewith
other TAVI experience. It was emphasized, however, that the
procedures are technically demanding and should be reserved
for high-volume centers. Ostial left main obstruction can be
a concern, especially when using specific bioprosthetic
devices.16,17 Significantly elevated postprocedural gradients
were commonly observed in relatively small bioprosthetic
devices treated with currently available Edwards Sapien
prostheses.
EUROPEAN MARKET
To date, more than 60,000 transcatheter aortic valve pros-
theses have been implanted worldwide. Although the an-
nual growth rate has slowed, in 2011, it was still 47%
(BIBA Medical Ltd, London, United Kingdom; a provider
of market analysis for the medical device industry). The to-
tal number of implants has varied among the major Euro-
pean countries. According to the official statistics of the
German Society for Thoracic and Cardiovascular Surgery,
5083 TAVI procedures were performed in 2011, accountingdiovascular Surgery c Volume 145, Number 3S S17
Panel 1 Lange et alS1Abbreviations and Acronyms
euroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
HTA ¼ health technology assessment
TA ¼ transapical
TAVI ¼ transcatheter aortic valve
implantation
TF ¼ transfemoral8 The Journfor 30.5% of all isolated aortic valve procedures in Ger-
many (DGTHG Leistungsstatistik 2011). Nonetheless,
TAVI penetration rates have been less than 20% in Europe,
according to data presented by Nicolo Piazza, MD, at the
2011 PCR London Valves Congress in London, United
Kingdom. The distribution of implant procedures for the
main European countries was as follows: Germany, 43%;
Italy and France, 11%; Spain and United Kingdom, 7%;
The Netherlands, 6%; and Switzerland, 4%. The number
of implants per 1 million inhabitants was greatest for Swit-
zerland and Germany, with 77 implants per 1 million, fol-
lowed by Austria at 50/1 million, The Netherlands at 49/1
million, Belgium at 40/1 million, Denmark at 39/1 million,
Italy at 27/1 million, France at 24/1 million, Spain at 21/1
million, Sweden at 20/1 million, Finland at 17/1 million,
United Kingdom/Ireland at 16/1 million, Portugal at 13/1
million, and Norway at 12/1 million, respectively (BIBA
Medical Ltd).
REIMBURSEMENT
A health technology assessment (HTA) describes the sys-
tematic evaluation of health-relevant procedures and
methods (ie, vaccinations, medical treatments, preventative
measures) and examines the effectiveness, safety, and eco-
nomic viability of a health intervention, as well as its social,
ethical, legal, and organizational effects and thus serves as
the basis for decisions in the health system (DIMDI, Ger-
man Institute of Medical Documentation and Information,
Cologne, Germany). Such a systematic evaluation of
TAVI has not yet been performed in all European countries.
According to the data presented by Nicolo Piazza, MD, at
the 2011 PCR London Valves Congress in London, United
Kingdom, the United Kingdom has not yet performed an
HTA, because they await randomized trial data. The TAVI
procedures are thus funded within the hospital budget. In
Belgium and The Netherlands, the HTA review provided
negative findings, with clinical data only (no economic
data), and funding was declined. In these hospitals, TAVI
procedures are funded within the hospital budget. In Ger-
many, an HTA review is currently not required. After CE
mark approval, the respective diagnosis-related groupal of Thoracic and Cardiovascular Surgreimbursement system is sufficient to cover the procedures.
In Italy, a regional HTA is ongoing, and reimbursement is
also regional. In Spain, the regional HTA is still ongoing,
and the TAVI procedures are funded within the hospital
budget. In France, there was a national HTA, resulting in
a positive HTA review from clinical data only (no economic
data), and implantations are restricted to 33 implanting cen-
ters and inoperable patients.
Hence, the TAVI reimbursement process is different
across the European countries. Reimbursement assessment
can be performed at a national or regional level, and in dif-
ferent countries, reimbursement might or might not require
a formal HTA review process. In summary, reimbursement
for TAVI is a dynamic process that is currently undergoing
rapid change.
MAJOR INDUSTRY-SPONSORED EUROPEAN
STUDIES
Two postcommercialization studies have been per-
formed, both of which were sponsored by the manufacturer
of the respective valve prosthesis used.
The first trial was the Edwards SOURCE TA and TF Trial
using the Edwards SAPIEN prosthesis (Edwards LifeScien-
ces). The 1-year analysis (97.9% compliance) of the entire
cohort of 2307 patients for this multicenter study was pre-
sented by Dr Olaf Wendler (Kings College Hospital, Lon-
don, United Kingdom) at the EuroPCR 2011: Congress of
the European Association of Percutaneous Cardiovascular
Interventions (May 17-20, 2011, Paris, France).18
Significant differences were seen between the transfe-
moral (TF) (n ¼ 920) and transapical (TA) (n ¼ 1387)
groups, with a significantly greater rate of comorbidities
in the TA group. Adverse events up to 30 days showed no
differences between the TF and TA groups regarding the
incidence of stroke (2.9% and 2.5%), acute myocardial in-
farction (0.9% and 0.5%), perivalvular leakage greater than
aortic regurgitation 2þ (6.7% and 4.3%), and endocarditis.
However, significantly more major bleeding events (6.7%
vs 1.8%, P<.04) and a greater incidence of renal failure
requiring dialysis (3.9% vs 2.3%, P<.001) were observed
in the TA than in the TF group. In contrast, the TF group ex-
hibited significantly more major vascular access-related
complications (11.3% vs 2.0%, P<.001). For the entire co-
hort of 2307 patients, the overall 30-day and 1-year survival
was 90.5% and 76.5%, respectively. For the TF group, the
corresponding percentages were 92.5% and 81.1% and for
the TA group were 89.1% and 74.2%.
The second trial was the Medtronic Advance Trial with
the Medtronic CoreValve prosthesis. The Medtronic Ad-
vance Study was designed to evaluate the safety, efficacy,
and clinical outcomes, using the Valve Academic Research
Consortium criteria, of the CoreValve system in 1015 con-
secutive ‘‘real world’’ patients with severe aortic stenosis.
Major complications included valve embolization inery c March 2013
FIGURE 1. Currently approved CE mark transcatheter aortic valves: A, Edwards SAPIEN XT; B, Medtronic CoreValve; C, JenaValve; and D, Symetis.
Lange et al Panel 10.3%, the need for conversion to open aortic valve replace-
ment in 0.1%, and compromise of coronary perfusion in
0.1%. The effective orifice area remained unchanged for
up to 6 months, and symptomatic improvement in terms
of New York Heart Association class was observed in al-
most all patients. All-cause mortality at 30 days or less
was 4.5%, and cardiovascular mortality was 3.4%. The in-
cidence of strokewas 2.9%, major bleeding events were ob-
served in 9.7%, vascular access site complications in
10.7%, and acute kidney injury in 0.4%. Also, 26.3% of
the patients required new permanent pacemaker implanta-
tion. The 6-month survival stratified by European SystemTABLE 1. Transaortic series
Investigator Patients (n) Technique
Moat13 93 Right minithoracotomy in 52.2%;
upper ministernotomy in 47.5%
Bapat14 158 Upper ministernotomy in 87%;
right minithoracotomy in 13%
The Journal of Thoracic and Carfor Cardiac Operative Risk Evaluation (euroSCORE) was
95.7% for those with a euroSCORE of 0% to 10%,
92.4% for a euroSCORE of 10% to 20%, and 88.1% for
those with a euroSCORE greater than 20%.
EUROPEAN SINGLE-CENTER MID-TERM
EXPERIENCE
In 4 major European single-center studies, the mean aor-
tic gradient and effective orifice area were shown to remain
unchanged for up to 3 years after implantation of the Med-
tronic CoreValve prosthesis and Edwards Sapien prosthe-
sis.19-22 Their results (Table 2) demonstrated strikinglyProsthesis 30-d Mortality (%) Stroke incidence (%)
CoreValve 9.7% 3.2%
Sapien 7% 0%
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TABLE 2. Survival up to 3 years with CoreValve and Sapien valves
Author Patients (n) Prosthesis
Survival (%)
1 y 2 y 3 y
Walther et al19 299 Sapien 73% 68% 58%
Ussia et al20 181 CoreValve 76.4% 69.7% 56.2%
Bleiziffer et al21 227 Sapien plus
CoreValve
74.5% 64.4% —
Buellesfeld et al22 126 CoreValve — 61.9% —
Panel 1 Lange et alsimilar mid-term survival data, regardless of the access
route or prosthesis type used.EUROPEAN REGISTRIES
Data are available from the national registries of 6
different European countries: Germany (1387 patients), the
United Kingdom (877 patients), Belgium (600 patients),
Italy (663 patients), France (2419 patients), and Spain
(108 patients).23,24 All registries included the Medtronic
CoreValve and Edwards Sapien prostheses. It is remarkable
that a trend toward a decrease in the euroSCORE over time
was observed in most registries and that the overall results
in terms of adverse events and survival have been
comparable. However, these very early registry data should
be regarded with caution. In some countries, such as
Germany, an obligatory national registry was only recently
started, and the results are not yet available. The registry
cited in the present report was from a multicenter German
study that does not reflect the entire German data set.
Similarly, in other countries, the registries might report
very early results and be incomplete. Furthermore, not all
registries collect the data according to the same standards,
such as the Valve Academic Research Consortium criteria;
thus, comparisons among different registry results might
not be accurate.
The logistic euroSCORE of patients reported in these reg-
istries lieswithin a small range: from20.5% (inGermany) to
26% (in Belgium). The only outlier was Spain at 16%. The
30-day and 1-year survival have been reported to be in the
range of 88.8% (in Germany) to 94.6% (in the United King-
dom) and from 76% (in France) to 85% (in Italy). In con-
trast, a marked difference has been reported in the
incidence of vascular complications, ranging from 3.9% in
the United Kingdom up to 16.9% in Germany. This consid-
erable variation could also reflect different standards for data
reporting and the use of different access routes.
Recently, a true National German Aortic Registry was
established, and enrollment started in December 2010.
This registry compiles the data of all surgical and trans-
catheter aortic valve procedures in Germany. Participa-
tion is mandatory, and nonreporting centers are
published in the ‘‘Journal of the Deutsche Herzstiftung’’
(German Heart Foundation). By April 19, 2012, 22,473S20 The Journal of Thoracic and Cardiovascular Surgpatients had given consent, and their data were being
transmitted to the registry. Of the procedures reported,
71% were conventional aortic valve replacements, 20%
transarterial TAVI procedures, 8% transapical TAVI pro-
cedures, and 1% valvuloplasties. Data from this registry
were reported for the first time at the 2012 European
Society of Cardiology Congress in Munich, Germany
(August 25-29, 2012).
A GLIMPSE OF THE FUTURE
Similar to coronary stent use for off-label indications,
evidence has shown that, in Europe, the patient selection
criteria for TAVI are evolving away from the premarket
inclusion and exclusion criteria. Thus, it seems that
transcatheter aortic valves are being implanted in lower
risk patients than those originally included in the initial
safety and feasibility trials. We recently published
a study in which 420 patients undergoing TAVI were
subdivided into 4 equal quartiles (each quartile with
105 patients) according to the enrollment period.25 The
4 subgroups were subsequently analyzed for differences
in baseline characteristics and clinical outcomes. The
crude 30-day and 6-month mortality rates improved
from quartile 1 to quartile 4. However, after adjustment
for patient risk factors, no significant differences in mor-
tality were observed between the quartiles, suggesting
that changing baseline characteristics might, in part, ex-
plain the observed differences in crude mortality. We ob-
served a shift toward the treatment of younger patients
with fewer comorbidities and lower surgical risk (logis-
tic euroSCORE and Society of Thoracic Surgeons
score). The results of that study suggested that improved
survival outcomes can be expected in lower surgical risk
patients undergoing TAVI.
The extent of this paradigm shift and its effect on
clinical outcomes, however, are still uncertain. The Med-
tronic CoreValve Surgical Replacement and Transcatheter
Aortic Valve Implantation (SURTAVI) trial and Edwards
Placement of AoRTic TraNscathetERValve (PARTNER 2)
SAPIEN XT trial will randomize intermediate- to high-
surgical risk patients to TAVI or surgical aortic valve
replacement. These trials should provide us with yet an-
other indication that TAVI is being directed at the treat-
ment of lower risk and lower surgical risk patients.
TheSURTAVI trial,which startedenrollment inApril 2012,
is expected to randomize 2000 patients older than 70 years
with aortic stenosis and at intermediate surgical risk (defined
by an Society of Thoracic Surgeons score of 3%-10% in Eu-
rope and Canada and 4%-10% in the United States) to con-
ventional surgery or TAVI with the Medtronic CoreValve. In
the PARTNER 2 trial, intermediate-risk patients are random-
ized after the decision regardingTF or TA access to surgery or
TAVI. These are noninferiority trials, with primary endpoints
of all-cause mortality and major stroke at 2 years.ery c March 2013
Lange et al Panel 1CONCLUSIONS
The European TAVI experience began in 2002, and ever
since, numerous centers have started a program, resulting
in a ‘‘TAVI pandemic.’’ Considerable experience has been
gained with various access routes for implantation and
with valve in surgical bioprosthetic valve procedures. Reim-
bursement differs among the European countries and is cur-
rently undergoing rapid changes. Accordingly, implantation
rates in various European countries still differ considerably,
with the greatest in Switzerland and Germany: 77 implants/
1 million treatable inhabitants. The Edwards Source and the
Medtronic Advance trials, designed as postcommercializa-
tion studies, have demonstrated a steady improvement in re-
sults, which was also reflected in the single-center mid-term
data up to 3 years. Preliminary results from the national Eu-
ropean registries have been remarkably comparable in terms
of survival and stroke. The ‘‘glimpse into the future’’ points
toward implantation in intermediate-risk patients instead of
high-risk or inoperable patients. The results of the Med-
tronic SURTAVI and Edwards PARTNER 2 trial will
show whether this change in paradigm is justified.References
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